https://www.selleckchem.com/pr....oducts/Aloxistatin.h
efore be discussed with caution, taking both risk of relapse and efficacy of re-treatment into account. Mitsubishi Tanabe Pharma Corporation and the Intractable Disease Project of the Ministry of Health, Labour and Welfare of Japan. For the Japanese translation of the abstract see Supplementary Materials section. For the Japanese translation of the abstract see Supplementary Materials section. The aim of this study was to evaluate the incidence, severity, and treatment modalities of retinopathy of prematurity (ROP) in moderate and l
Curtir
Comentario
Compartilhar
